Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | CTRC | Q99895 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891774 | 1.00 | MAPT (0.47) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL755504 | 0.83 | MAPT (0.45) | MAPTACHESIGMAR1 | |
| SCHEMBL22873345 | 0.83 | MAPT (0.45) | MAPTACHESIGMAR1 | |
| SCHEMBL15648976 | 0.83 | MAPT (0.45) | MAPTACHEHPGDSIGMAR1ALDH1A1 | |
| SCHEMBL3056314 | 0.82 | CHRM2 (0.44) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL15700421 | 0.82 | CHRM2 (0.44) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL3056318 | 0.82 | CHRM2 (0.44) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL3056320 | 0.82 | CHRM2 (0.44) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL6204136 | 0.82 | CHRM2 (0.44) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL4983527 | 0.78 | EP300 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814699-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-06-09 | — | — | US | disclosed |
| EP-3006441-A1 | NS5A INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150374668-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2015-12-31 | — | — | US | disclosed |
| US-9150587-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2015-10-06 | — | — | US | disclosed |
| CN-102229605-B | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALY SRL | 2015-01-14 | — | — | CN | disclosed |
| US-20140371455-A1 | Chemical compounds | JANSSEN PHARMACEUTICALS INC (US) | 2014-12-18 | — | — | US | disclosed |
| US-8492554-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130072690-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2473056-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-0659178-A4 | CHIRAL QUINOLONE INTERMEDIATES. | ABBOTT LAB (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0659178-A1 | CHIRAL QUINOLONE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994006766-A1 | CHIRAL QUINOLONE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5252747-A | Chiral quinolone intermediates | ABBOTT LABORATORIES (US) | 1993-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374668-A1 | CHEMICAL COMPOUNDS | SLC10A1, UGT1A3, UGT2B7 | MAPT 2480/4885CSNK2A2 1612/4885CSNK2B 1399/4885 |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | SLC10A1, UGT1A3, UGT2B7 | MAPT 2480/4885CSNK2A2 1612/4885CSNK2B 1399/4885 |
| US-20140371455-A1 | Chemical compounds | SLC10A1, UGT1A3, UGT2B7 | MAPT 2480/4885CSNK2A2 1612/4885CSNK2B 1399/4885 |
| US-20130072690-A1 | Chemical Compounds | SLC10A1, UGT1A3, UGT2B7 | MAPT 2480/4885CSNK2A2 1612/4885CSNK2B 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.